AngioDynamics Inc Q4 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Great. Just a little more color on the question for procedures. How that looks intra-quarter again given your May end quarter? I was wondering if you could give us a little more detail geographically. Is there any nuances that we should be kind of aware of if you look around the globe relative to the COVID impact on procedures and kind of where you think you are today? As you said, you're not all the way there. Are we 95%? And if so, 90%? And when do we expect to get to 100%? And just a little more granularity relative to the geographic segments. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 13, 2021 / 12:00PM, ANGO.OQ - Q4 2021 AngioDynamics Inc Earnings Call

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Okay. That's helpful. And then in terms of the Auryon on guidance, you did $4.6 million. You're guiding $18 million to $22 million. Matt says $4.6 million is a little above the low end of that range. And I'm just wondering, is there something -- are you shifting more to disposable and less capital? Or why would we see a little higher growth?

Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst : Okay. And then last question is, you've made a lot of investments. It seems you're signaling that with the new terminology, the medical technology versus the medical devices, that it's really focused on the 3 product lines. When -- you've made a lot of investments, but when should we expect to see you start harvesting those investments and leverage that into the model in terms of cash flow and earnings? And maybe that's an Investor Day question, and we can table that as well.